HL-040XC

· HanAll Biopharma Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for HL-040XC, covering 2013-03-07 to 2015-09-23. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia [Phase 3]